Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + cytarabine + dexamethasone + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + vincristine + carboplatin + lomustine + carmustine + melphalan + idarubicin
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intrathecal, Subcutaneous
01
Overview
This is a complex combination chemotherapy regimen containing multiple cytotoxic and antineoplastic agents. The combination includes alkylating agents (cyclophosphamide, ifosfamide, carmustine, lomustine, melphalan), antimetabolites (cytarabine, methotrexate), anthracyclines (doxorubicin hydrochloride, idarubicin), vinca alkaloids (vincristine), platinum compounds (carboplatin), topoisomerase inhibitors (etoposide), and corticosteroids (dexamethasone). Each component works through different mechanisms to target rapidly dividing cancer cells.
02
Targets
DHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + cytarabine + dexamethasone + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + vincristine + carboplatin + lomustine + carmustine + melphalan + idarubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + cytarabine + dexamethasone + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + vincristine + carboplatin + lomustine + carmustine + melphalan + idarubicin.